Publicaciones (44) Publicaciones de JAVIER DE JUAN BAGUDA

2024

  1. Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure

    ESC Heart Failure

  2. Evolution of the impact of the COVID-19 pandemic on heart transplant recipients: Decreasing risk, improving perspective

    Transplant Infectious Disease, Vol. 26, Núm. 2

  3. Repetitive ambulatory levosimendan as a bridge to heart transplantation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 290-301

  4. Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document

    Revista Espanola de Cardiologia, Vol. 77, Núm. 1, pp. 69-78

2023

  1. Baroreflex activation therapy in patients with heart failure and reduced ejection fraction

    Revista Espanola de Cardiologia

  2. Conduction system pacing and atrioventricular node ablation in heart failure: The PACE-FIB study design

    ESC Heart Failure, Vol. 10, Núm. 6, pp. 3700-3709

  3. De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  4. Do Women Physicians Accept and Follow Heart Failure Guidelines More Than Men?

    Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 151-156

  5. Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 2875-2881

  6. Impacto del seguimiento precoz desde atención primaria en el reingreso a 30 días tras el alta hospitalaria por insuficiencia cardiaca: (Pag.-e 101911)

    Semergen: revista española de medicina de familia, Núm. 2, pp. 4-4

  7. Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

    Clinical Research in Cardiology

  8. Intermittent hypoxic-hyperoxic conditioning for heart failure rehabilitation

    REC: CardioClinics, Vol. 58, Núm. 2, pp. 79-87

  9. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 1193-1204

  10. Opinion on the 2021 ESC guidelines on heart failure: a cross-sectional survey of 387 doctors

    REC: CardioClinics, Vol. 58, Núm. 1, pp. 7-15

  11. Selection of the best of 2022 in heart failure

    REC: CardioClinics, Vol. 58, pp. S42-S48

  12. Twenty-four hour ambulatory blood pressure monitoring in patients with stable heart failure. Prevalence and associated factors

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 852-861

  13. Vericiguat in the current management of the patients with heart failure

    REC: CardioClinics

2022

  1. Clinical Utility of HeartLogic, a Multiparametric Telemonitoring System, in Heart Failure

    Cardiac Failure Review, Vol. 8

  2. Dose of furosemide before admission predicts diuretic efficiency and long-term prognosis in acute heart failure

    ESC Heart Failure, Vol. 9, Núm. 1, pp. 656-666

  3. Impact of blood pressure on management and prognosis of patients treated with sacubitril/valsartan

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 116-122